Roquefort Therapeutics (LON:COIL) Stock Price Down 7.9% – What’s Next?

Roquefort Therapeutics plc (LON:COIL) shares dropped 7.9% during mid-day trading on Monday . The company traded as low as GBX 7.50 and last traded at GBX 8.38. Approximately 590,331 shares changed hands during trading, an increase of 139% from the average daily volume of 246,579 shares. The stock had previously closed at GBX 9.10.

Roquefort Therapeutics Stock Performance

The company has a quick ratio of 3.07, a current ratio of 2.80 and a debt-to-equity ratio of 8.07. The stock has a market cap of £35.69 million, a P/E ratio of -1.33 and a beta of 0.05. The stock has a fifty day simple moving average of GBX 10.37 and a 200-day simple moving average of GBX 14.19.

About Roquefort Therapeutics

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.